PoplarV1, Main, Exploration, bibRecord, 004251

ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.

Identifieur interne : 004251 ( Main/Exploration ); précédent : 004250; suivant : 004252

ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.

Auteurs : M J Pearse [Australie] ; D. Drane

Source :

Vaccine [ 0264-410X ] ; 2004.

RBID : pubmed:15193400

Descripteurs français

KwdFr :
- Adjuvants immunologiques (administration et posologie), Adjuvants immunologiques (pharmacologie), Animaux (MeSH), Humains (MeSH), Immunité cellulaire (effets des médicaments et des substances chimiques), Lymphocytes T CD4+ (immunologie), Lymphocytes T CD8+ (immunologie), Production d'anticorps (effets des médicaments et des substances chimiques), Vaccins (administration et posologie).
MESH :
- administration et posologie : Adjuvants immunologiques, Vaccins.
- effets des médicaments et des substances chimiques : Immunité cellulaire, Production d'anticorps.
- immunologie : Lymphocytes T CD4+, Lymphocytes T CD8+.
- pharmacologie : Adjuvants immunologiques.
- Animaux, Humains.

English descriptors

KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adjuvants, Immunologic (pharmacology), Animals (MeSH), Antibody Formation (drug effects), CD4-Positive T-Lymphocytes (immunology), CD8-Positive T-Lymphocytes (immunology), Humans (MeSH), Immunity, Cellular (drug effects), Vaccines (administration & dosage).
MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Vaccines.
- chemical , pharmacology : Adjuvants, Immunologic.
- drug effects : Antibody Formation, Immunity, Cellular.
- immunology : CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes.
- Animals, Humans.

Abstract

ISCOMATRIX adjuvant is capable of inducing broad and potent humoral and cellular immune responses. The components are well defined and the manufacturing process is simple and robust. Many vaccines containing the ISCOMATRIX adjuvant have been tested in a range of animal models, including human and non-human primates. Strong antibody and T cell responses have been induced in these studies. The antibody response is often achieved with lesser amounts of antigen than other adjuvant systems and the maximal responses have also been reached more quickly. Both CD4+ and CD8+ T cell responses are induced with the cytotoxic T lymphocyte responses being very long lived. Additionally, ISCOMATRIX adjuvant can be used in vaccines for induction of mucosal immune responses. This review provides an overview of the immune responses that can be elicited using ISCOMATRIX vaccines and the current state of knowledge regarding the mechanism of action of this adjuvant.

DOI: 10.1016/j.vaccine.2003.12.031
PubMed: 15193400

Affiliations:

Australie

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 004256
to stream Main, to step Curation: 004256

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.</title>
<author><name sortKey="Pearse, M J" sort="Pearse, M J" uniqKey="Pearse M" first="M J" last="Pearse">M J Pearse</name>
<affiliation wicri:level="1"><nlm:affiliation>CSL Limited, 45 Poplar Road, Parkville, Vic., Australia. martin.pearse@csl.com.au</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>CSL Limited, 45 Poplar Road, Parkville, Vic.</wicri:regionArea>
<wicri:noRegion>Vic.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Drane, D" sort="Drane, D" uniqKey="Drane D" first="D" last="Drane">D. Drane</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15193400</idno>
<idno type="pmid">15193400</idno>
<idno type="doi">10.1016/j.vaccine.2003.12.031</idno>
<idno type="wicri:Area/Main/Corpus">004256</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">004256</idno>
<idno type="wicri:Area/Main/Curation">004256</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">004256</idno>
<idno type="wicri:Area/Main/Exploration">004256</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.</title>
<author><name sortKey="Pearse, M J" sort="Pearse, M J" uniqKey="Pearse M" first="M J" last="Pearse">M J Pearse</name>
<affiliation wicri:level="1"><nlm:affiliation>CSL Limited, 45 Poplar Road, Parkville, Vic., Australia. martin.pearse@csl.com.au</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>CSL Limited, 45 Poplar Road, Parkville, Vic.</wicri:regionArea>
<wicri:noRegion>Vic.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Drane, D" sort="Drane, D" uniqKey="Drane D" first="D" last="Drane">D. Drane</name>
</author>
</analytic>
<series><title level="j">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Adjuvants, Immunologic (pharmacology)</term>
<term>Animals (MeSH)</term>
<term>Antibody Formation (drug effects)</term>
<term>CD4-Positive T-Lymphocytes (immunology)</term>
<term>CD8-Positive T-Lymphocytes (immunology)</term>
<term>Humans (MeSH)</term>
<term>Immunity, Cellular (drug effects)</term>
<term>Vaccines (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term>
<term>Adjuvants immunologiques (pharmacologie)</term>
<term>Animaux (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Immunité cellulaire (effets des médicaments et des substances chimiques)</term>
<term>Lymphocytes T CD4+ (immunologie)</term>
<term>Lymphocytes T CD8+ (immunologie)</term>
<term>Production d'anticorps (effets des médicaments et des substances chimiques)</term>
<term>Vaccins (administration et posologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Vaccins</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Antibody Formation</term>
<term>Immunity, Cellular</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Immunité cellulaire</term>
<term>Production d'anticorps</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes T CD4+</term>
<term>Lymphocytes T CD8+</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD4-Positive T-Lymphocytes</term>
<term>CD8-Positive T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">ISCOMATRIX adjuvant is capable of inducing broad and potent humoral and cellular immune responses. The components are well defined and the manufacturing process is simple and robust. Many vaccines containing the ISCOMATRIX adjuvant have been tested in a range of animal models, including human and non-human primates. Strong antibody and T cell responses have been induced in these studies. The antibody response is often achieved with lesser amounts of antigen than other adjuvant systems and the maximal responses have also been reached more quickly. Both CD4+ and CD8+ T cell responses are induced with the cytotoxic T lymphocyte responses being very long lived. Additionally, ISCOMATRIX adjuvant can be used in vaccines for induction of mucosal immune responses. This review provides an overview of the immune responses that can be elicited using ISCOMATRIX vaccines and the current state of knowledge regarding the mechanism of action of this adjuvant.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15193400</PMID>
<DateCompleted><Year>2004</Year>
<Month>09</Month>
<Day>07</Day>
</DateCompleted>
<DateRevised><Year>2005</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0264-410X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>22</Volume>
<Issue>19</Issue>
<PubDate><Year>2004</Year>
<Month>Jun</Month>
<Day>23</Day>
</PubDate>
</JournalIssue>
<Title>Vaccine</Title>
<ISOAbbreviation>Vaccine</ISOAbbreviation>
</Journal>
<ArticleTitle>ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.</ArticleTitle>
<Pagination><MedlinePgn>2391-5</MedlinePgn>
</Pagination>
<Abstract><AbstractText>ISCOMATRIX adjuvant is capable of inducing broad and potent humoral and cellular immune responses. The components are well defined and the manufacturing process is simple and robust. Many vaccines containing the ISCOMATRIX adjuvant have been tested in a range of animal models, including human and non-human primates. Strong antibody and T cell responses have been induced in these studies. The antibody response is often achieved with lesser amounts of antigen than other adjuvant systems and the maximal responses have also been reached more quickly. Both CD4+ and CD8+ T cell responses are induced with the cytotoxic T lymphocyte responses being very long lived. Additionally, ISCOMATRIX adjuvant can be used in vaccines for induction of mucosal immune responses. This review provides an overview of the immune responses that can be elicited using ISCOMATRIX vaccines and the current state of knowledge regarding the mechanism of action of this adjuvant.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pearse</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>CSL Limited, 45 Poplar Road, Parkville, Vic., Australia. martin.pearse@csl.com.au</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Drane</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Vaccine</MedlineTA>
<NlmUniqueID>8406899</NlmUniqueID>
<ISSNLinking>0264-410X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014612">Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014612" MajorTopicYN="N">Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>27</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>9</Month>
<Day>8</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>6</Month>
<Day>15</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15193400</ArticleId>
<ArticleId IdType="doi">10.1016/j.vaccine.2003.12.031</ArticleId>
<ArticleId IdType="pii">S0264410X04002476</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
</country>
</list>
<tree><noCountry><name sortKey="Drane, D" sort="Drane, D" uniqKey="Drane D" first="D" last="Drane">D. Drane</name>
</noCountry>
<country name="Australie"><noRegion><name sortKey="Pearse, M J" sort="Pearse, M J" uniqKey="Pearse M" first="M J" last="Pearse">M J Pearse</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004251 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004251 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    PoplarV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:15193400
   |texte=   ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:15193400" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a PoplarV1

This area was generated with Dilib version V0.6.37.
Data generation: Wed Nov 18 12:07:19 2020. Site generation: Wed Nov 18 12:16:31 2020

	Serveur d'exploration sur le peuplier
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le peuplier

ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.

ISCOMATRIX adjuvant: a potent inducer of humoral and cellular immune responses.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki